U.S. Health and Human Services Secretary Robert F. Kennedy Jr., testifies before a Senate Finance Committee hearing on President Donald Trump’s 2026 health care agenda, on Capitol Hill in Washington, D.C., U.S., September 4, 2025. Jonathan Ernst | Reuters Health and Human Services Secretary Robert F. Kennedy Jr. doubled down on false claims about vaccines…
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. We’re inching closer to having the first-ever needle-free weight loss drug. That’s thanks to Novo Nordisk, which expects a U.S. approval for its daily pill for chronic…
A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters The Centers for Disease Control and Prevention told staff it expects them to return to offices by Sept. 15, roughly five weeks after a…
The exterior of the Center for Disease Control and Prevention (CDC) main campus in Atlanta, Georgia, U.S., Aug. 27, 2025. Alyssa Pointer | Reuters The Centers for Disease Control and Prevention is facing a leadership upheaval — and at the center of the shakeup is concern about the agency’s approach to vaccines and U.S. public…
Susan Monarez, President Donald Trump’s nominee to be the Director of the Centers for Disease Control and Prevention (CDC), testifies during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions in the Dirksen Senate Office Building on June 25, 2025 in Washington, DC. Kayla Bartkowski | Getty Images Centers for Disease…
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | Reuters Eli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to…
Eternalcreative | Istock | Getty Images Miracle drugs, obesity treatments and skinny jabs. Call them what you will, few drugs have had a more transformative effect on Wall Street and waistlines over recent decades than GLP-1s. Familiarly known under the brand names Wegovy and Zepbound, Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medication used to…
A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly‘s stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial,…
U.S. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. speaks as he attends a press conference with Centers for Medicare and Medicaid Services Administrator Mehmet Oz to discuss health insurance reform, at the Department of Health and Human Services in Washington, D.C., U.S., June 23, 2025. Kevin Mohatt | Reuters A version of…
Wegovy injection pens arranged in Waterbury, Vermont, US, on Monday, April 28, 2025. Shelby Knowles | Bloomberg | Getty Images Shares of Novo Nordisk climbed almost 5% Monday after the company’s blockbuster Wegovy obesity drug received accelerated approval from the U.S. Food and Drug Administration to treat a serious liver disease. The company on Friday…
